Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM.
De Vita
S
S
De Matteis
S
S
Laurenti
L
L
Chiusolo
P
P
Sorà
F
F
Piccirillo
N
N
Reddiconto
G
G
Fiorini
A
A
Leone
G
G
Sica
S
S
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D001932:Brain Neoplasms / Q000188:drug therapy*; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000235:genetics; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate